The advent of BRAF inhibitors and immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of melanoma patients. However, melanoma subtypes such as limbal, mucosal, and uveal melanomas are less responsive to these therapies than cutaneous melanomas, and new therapeutic agents are urgently needed for treatment-resistant patients. Antibody-drug conjugates (ADCs) achieve...
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek